Interferon alfa-2a contraindications: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| (One intermediate revision by the same user not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Interferon alfa-2a}} | {{Interferon alfa-2a}} | ||
{{CMG}} | {{CMG}}; {{AE}} {{SS}} | ||
==Contraindications== | ==Contraindications== | ||
| Line 7: | Line 7: | ||
*Hypersensitivity to Roferon-A or any of its components | *Hypersensitivity to Roferon-A or any of its components | ||
*Autoimmune | *Autoimmune hepatitis | ||
*Hepatic decompensation (Child-Pugh class B and C) before or during treatment | *Hepatic decompensation (Child-Pugh class B and C) before or during treatment | ||
Latest revision as of 14:01, 9 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sheng Shi, M.D. [2]
Contraindications
Roferon-A is contraindicated in patients with:
- Hypersensitivity to Roferon-A or any of its components
- Autoimmune hepatitis
- Hepatic decompensation (Child-Pugh class B and C) before or during treatment
Roferon-A is contraindicated in neonates and infants because it contains benzyl alcohol. Benzyl alcohol is associated with an increased incidence of neurologic and other complications in neonates and infants, which are sometimes fatal.[1]
References
- ↑ "http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/103964s5204lbl.pdf" (PDF). External link in
|title=(help)
Adapted from the FDA Package Insert.